Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA plus decitabine for induction failure in elderly AML
ChiCTR-OIC-16008952Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine, idarubicin and cytarabine in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoints: Complete remission rate and Partial remission rate. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
decitabineidarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OIC-16008952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008952.